Navigation Links
Sinovac Reports Unaudited First Quarter 2011 Financial Results
Date:5/13/2011

BEIJING, May 13, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited first quarter financial results for the period ended March 31, 2011.

First Quarter 2011 Financial Highlights

  • Sales increased 5.3% year-over-year to $4.7 million, compared to $4.4 million. Excluding H1N1 vaccine, sales rose 50% compared to the prior year period.

  • Cash and cash equivalents totaled $91.0 million as of March 31, 2011, compared to $101.6 million as of December 31, 2010.

  • Business Highlights

  • Sinovac has enrolled 168 healthy volunteers in three different groups (36 adults, 36 young children and 96 infants) in the Phase I clinical trial for EV71 vaccine. The inoculations with different dosages have been completed in the young children group and are underway in the infant group, which is expected to be completed in the next few weeks. The preliminary results showed good safety and tolerance profile without severe adverse reaction.

  • In April 2011, Sinovac submitted the application to the SFDA to commence clinical trials for its rubella vaccine.  

  • In April 2011, the Ministry of Agriculture (MOA) conducted the final GMP site inspection of Sinovac's animal rabies vaccine production plant in Tangshan Yian, which was conducted under the production mode.  The preliminary site inspection results were positive and are subject to a public notification period that ends on May 18, 2011, after which Tangshan Yian will apply for the GMP Certificate, the New Drug Certificate and the production license in advance of commercializing the vaccine.

  • Dr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "Following the adjustment to our sales strategy and sales team structure, our sales in China rebounded during t
    '/>"/>

    SOURCE Sinovac Biotech Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine technology :

    1. Sinovac Presents at Two Investor Conferences in May 2011
    2. Sinovac Files Annual Report on Form 20-F
    3. Sinovac Participates in UBS Greater China Healthcare Corporate Day
    4. Sinovac Reports Positive Preliminary Phase I Clinical Trial Results for EV71 Vaccine in Adult Group
    5. Sinovac Biotech Submits Clinical Trial Application to SFDA for Pneumococcal Conjugate Vaccine (PCV)
    6. Sinovac Provides Preliminary Unaudited Fourth Quarter 2010 Sales Range
    7. Sinovacs Stock Exchange Listing Moves to NASDAQ Global Select Market
    8. Sinovac Receives SFDA Approval to Commence Clinical Trials for Inactivated Enterovirus Type 71 Vaccine
    9. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
    10. Sinovac Selected by Beijing CDC to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
    11. Sinovac Receives Drug Registration Certificate from Hong Kong Department of Health for Seasonal Flu Vaccine Anflu(R)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 /PRNewswire-USNewswire/ ... remote-controlled catheter (MARC) which could allow physicians to see ... stroke may hold promise, according to study authors who ... Surgery (SNIS) 11 th Annual Meeting in ... findings stand to advance the field of neurointervention, a ...
    (Date:7/29/2014)... NASHVILLE, Tenn. and NEW YORK ... and member of the executive management team of Caremark ... of PBM365 Media ( www.pbm365.com ).  PBM365 is the ... and unbiased reporting, insight, analysis and opinion on ... PBM365 will provide insightful and timely coverage of, ...
    (Date:7/29/2014)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its presence ... Clinical Lab Expo today by unveiling two booths (#1209 ... partnering with customers to redefine the value of the ... that they,re looking for a partner to help them ... offices," said Jack Phillips , president and CEO ...
    Breaking Medicine Technology:New Technology May Improve Visualization Of The Brain During Stroke Treatment 2New Technology May Improve Visualization Of The Brain During Stroke Treatment 3Drew Crawford Announces Launch of PBM365 Media 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4
    ... Inc . announced today that David A. Weber, Ph.D. , ... Board of Directors. Jay Lichter, Ph.D., managing director of Avalon Ventures, ... actively support the company as a member of the Board of ... to the Otonomy team, as his extensive experience in the development ...
    ... 2010 Amicus Therapeutics (Nasdaq: FOLD ), ... diseases, today announced that it has been awarded a ... Parkinson,s Research (MJFF) for the development of a novel, ...  The $500,000 award will be distributed over a period ...
    Cached Medicine Technology:Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 2Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 2Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 3Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 4Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinson's Disease 5
    (Date:7/29/2014)... HealthDay Reporter TUESDAY, July 29, 2014 ... a single dose of the hormone oxytocin quickly improved their ... Known as the "love hormone," oxytocin has been shown ... between mothers and their children. In this study, it ... brain that has long been associated with the processing of ...
    (Date:7/29/2014)... 29, 2014 During his 37 years in ... & Associates, has had a steady stream of college students ... students have now gone on to dental school and some ... the shadowing program helps college students find success. , For ... given them the chance to see a realistic view of ...
    (Date:7/29/2014)... that helps headache sufferers to record the severity and ... of a Griffith research study. , A new approach ... at coping with their triggers and is being led ... Basis of Health program. , He has developed an ... triggers of their headaches called Learning to Cope with ...
    (Date:7/29/2014)... (PRWEB) July 29, 2014 Child abuse law ... law students this week. The scholarship will help future lawyers ... and their families. , Steinger, Iscoe and Greene lawyers work ... want tomorrow’s attorneys to do the same. More than 6 ... according to the nonprofit Childhelp (retrieved 7/22/2014). , ...
    (Date:7/29/2014)... NJ (PRWEB) July 29, 2014 Helping ... is an immensely complex challenge that requires deep knowledge ... knowledge to improve therapeutic options and outcomes has been ... professor of biomedical engineering, since he joined the NJIT ... whose significance is underscored by substantial funding from sources ...
    Breaking Medicine News(10 mins):Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Arthur Bruce Dental Helps College Students 2Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2Health News:Continuing the Quest for Better Stroke Therapies 2Health News:Continuing the Quest for Better Stroke Therapies 3Health News:Continuing the Quest for Better Stroke Therapies 4
    ... VNUS(R) Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading ... venous reflux disease, today,announced the appointment of Peter Osborne ... Administration., Mr. Osborne joins VNUS with over 25 ... Osborne had served as the Company,s,Interim CFO since October ...
    ... 3 times weekly may increase risk, study suggests , , ... a Mediterranean diet rich in fish, fresh fruits and vegetables, ... their children against asthma and allergies, new research suggests. , ... included 468 mother and child pairs that were followed from ...
    ... Matters of the mind can affect matters of the heart. ... researchers has found that major anxiety and/or depression, can double ... This is one of the first studies to focus on ... were hospitalized for events such as a heart attack. , ...
    ... be saved , , FRIDAY, Jan. 18 (HealthDay News) -- If ... die from sudden cardiac arrest could be dramatically reduced. , ... calling for renewed efforts to teach CPR and to find ... the lifesaving technique. , "There is a tremendous opportunity for ...
    ... Jan. 18 LifeSync Corporation is,pleased to announce ... of Operations. Ms. McLane comes to LifeSync Corporation ... Johnson Company, where she,most recently held the position ... joining Cordis, Ms. McLane spent over 13,years at ...
    ... brain tumors, dual implantation of radioactive seeds and ... a study led by specialists at the Neuroscience ... University Hospital. , The study, published in the ... that patients treated with simultaneous implantation of radioactive ...
    Cached Medicine News:Health News:VNUS Medical Technologies Appoints Peter Osborne as Chief Financial Officer 2Health News:Mediterranean Diet for Mom Fends Off Asthma, Allergies in Kids 2Health News:Depression and anxiety can double chances of heart ailments 2Health News:Heart Association Renews Call for CPR Training 2Health News:Heart Association Renews Call for CPR Training 3Health News:LifeSync Corporation Appoints Nancy McLane as Senior Vice President Operations 2Health News:Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors 2
    Colloidal Gold Conjugated, Protein A - 12 OD...
    Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
    Colloidal Gold Conjugated, Protein G - 12 OD...
    Colloidal Gold Sol, 40 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
    Medicine Products: